[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635126":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":42,"responsibleParty":181,"collaborators":27,"id":183,"slug":184,"hasResults":185,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":185,"sex":191,"minAge":192,"maxAge":27,"enrollmentInfo":193,"targetDuration":27,"studyType":196,"phases":197,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":45,"whyStopped":27,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},{"fullName":5,"class":6},"Oculis","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"licaminlimab","EXPERIMENTAL","60 mg\u002FmL licaminlimab ophthalmic solution",[13,14],"Other: Artificial Tear Run-in","Drug: licaminlimab",{"label":16,"type":17,"description":18,"interventionNames":19},"Vehicle","PLACEBO_COMPARATOR","Vehicle of licaminlimab ophthalmic solution",[13,20],"Other: Vehicle of licaminlimab",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"OTHER","Artificial Tear Run-in","Artificial tear eye drop run-in three times daily (TID) for approximately 14 days.",[16,9],null,{"type":29,"name":9,"description":30,"armGroupLabels":31,"otherNames":27},"DRUG","Licaminlimab eye drops three times daily (TID) for 29 days.",[9],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Vehicle of licaminlimab","Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.",[16],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Oculis Chief Development Officer","CONTACT","617 928 5886","info@oculis.com",[43,57,66,75,85,94,103,113,123,133,142,152,161,171],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":27},"East West Eye Institute","RECRUITING","Aliso Viejo","California","92656","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-117.72712,33.56504,{"lat":55,"lon":54},{"facility":58,"status":45,"city":59,"state":47,"zip":60,"country":49,"countryCode":50,"cosmosGeoPoint":61,"geoPoint":65,"contacts":27},"Orange County Ophthalmology","Garden Grove","92843",{"type":52,"coordinates":62},[63,64],-117.94145,33.77391,{"lat":64,"lon":63},{"facility":67,"status":45,"city":68,"state":47,"zip":69,"country":49,"countryCode":50,"cosmosGeoPoint":70,"geoPoint":74,"contacts":27},"Global Research Management","Glendale","91204",{"type":52,"coordinates":71},[72,73],-118.25508,34.14251,{"lat":73,"lon":72},{"facility":76,"status":77,"city":78,"state":47,"zip":79,"country":49,"countryCode":50,"cosmosGeoPoint":80,"geoPoint":84,"contacts":27},"LoBue Laser and Eye Medical Center","NOT_YET_RECRUITING","Murrieta","92562",{"type":52,"coordinates":81},[82,83],-117.21392,33.55391,{"lat":83,"lon":82},{"facility":86,"status":45,"city":87,"state":47,"zip":88,"country":49,"countryCode":50,"cosmosGeoPoint":89,"geoPoint":93,"contacts":27},"Eye Research Foundation","Newport Beach","92664",{"type":52,"coordinates":90},[91,92],-117.92895,33.61891,{"lat":92,"lon":91},{"facility":95,"status":45,"city":96,"state":47,"zip":97,"country":49,"countryCode":50,"cosmosGeoPoint":98,"geoPoint":102,"contacts":27},"North Bay Eye Associates, Inc.","Petaluma","94954",{"type":52,"coordinates":99},[100,101],-122.63665,38.23242,{"lat":101,"lon":100},{"facility":104,"status":45,"city":105,"state":106,"zip":107,"country":49,"countryCode":50,"cosmosGeoPoint":108,"geoPoint":112,"contacts":27},"Vision Institute","Colorado Springs","Colorado","80907",{"type":52,"coordinates":109},[110,111],-104.82136,38.83388,{"lat":111,"lon":110},{"facility":114,"status":45,"city":115,"state":116,"zip":117,"country":49,"countryCode":50,"cosmosGeoPoint":118,"geoPoint":122,"contacts":27},"Segal Drug Trials, Inc.","Delray Beach","Florida","33484",{"type":52,"coordinates":119},[120,121],-80.07282,26.46146,{"lat":121,"lon":120},{"facility":124,"status":45,"city":125,"state":126,"zip":127,"country":49,"countryCode":50,"cosmosGeoPoint":128,"geoPoint":132,"contacts":27},"Oculus Research, Inc.","Garner","North Carolina","27529",{"type":52,"coordinates":129},[130,131],-78.61417,35.71126,{"lat":131,"lon":130},{"facility":134,"status":45,"city":135,"state":126,"zip":136,"country":49,"countryCode":50,"cosmosGeoPoint":137,"geoPoint":141,"contacts":27},"CORE, Inc","Shelby","28150",{"type":52,"coordinates":138},[139,140],-81.53565,35.29235,{"lat":140,"lon":139},{"facility":143,"status":45,"city":144,"state":145,"zip":146,"country":49,"countryCode":50,"cosmosGeoPoint":147,"geoPoint":151,"contacts":27},"Scott & Christie and Associates","Cranberry Township","Pennsylvania","16066",{"type":52,"coordinates":148},[149,150],-80.10714,40.68496,{"lat":150,"lon":149},{"facility":153,"status":45,"city":154,"state":145,"zip":155,"country":49,"countryCode":50,"cosmosGeoPoint":156,"geoPoint":160,"contacts":27},"Erie Retina Research","Erie","16507",{"type":52,"coordinates":157},[158,159],-80.08506,42.12922,{"lat":159,"lon":158},{"facility":162,"status":45,"city":163,"state":164,"zip":165,"country":49,"countryCode":50,"cosmosGeoPoint":166,"geoPoint":170,"contacts":27},"Total Eye Care, PA","Memphis","Tennessee","38119",{"type":52,"coordinates":167},[168,169],-90.04898,35.14953,{"lat":169,"lon":168},{"facility":172,"status":45,"city":173,"state":174,"zip":175,"country":49,"countryCode":50,"cosmosGeoPoint":176,"geoPoint":180,"contacts":27},"Piedmont Eye Center, Inc.","Lynchburg","Virginia","24502",{"type":52,"coordinates":177},[178,179],-79.14225,37.41375,{"lat":179,"lon":178},{"type":182,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100635126","phase-2-a-clinical-study-evaluating-licaminlimab-for-dry-eye-disease-100635126",false,"NCT07548632","A Clinical Study Evaluating Licaminlimab for Dry Eye Disease","A Phase 2b\u002F3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype","PREDICT-1","Key Inclusion Criteria:\n\n* Physician diagnosis of Dry Eye Disease in the past 6 months\n* Use of over-the-counter tears\n* Must agree to genotype testing\n\nKey Exclusion Criteria:\n\n\\- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.","ALL","18 Years",{"count":194,"type":195},160,"ESTIMATED","INTERVENTIONAL",[198,199],"PHASE2","PHASE3","The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.",[202],"Dry Eye Disease (DED)",[9,204,189,205,206],"OCS-02","genotype based development","Eye drops","2026-05-27",{"date":209,"type":210},"2026-05-29","ACTUAL",{"date":212,"type":210},"2026-04-16",{"date":214,"type":195},"2026-12",{"name":5,"class":6},14]